INKT
Income statement / Annual
Last year (2024), MiNK Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, MiNK Therapeutics, Inc.'s net income was -$10.78 M.
See MiNK Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00 |
$0.00 |
$2.70 B |
$0.00 |
$0.00 |
$689,626.00 |
| Cost of Revenue |
$215,437.00
|
$204,617.00
|
$30.95 B
|
$28.36 B
|
$55,060.00
|
$0.00
|
| Gross Profit |
$0.00
|
-$204,617.00
|
-$28.24 B
|
-$28.36 B
|
-$55,060.00
|
$689,626.00
|
| Gross Profit Ratio |
0
|
0
|
-10.44
|
0
|
0
|
1
|
| Research and Development Expenses |
$6.34 M
|
$15.49 M
|
$23.12 M
|
$13.97 M
|
$9.51 M
|
$19.65 M
|
| General & Administrative Expenses |
$4.31 B
|
$7.43 M
|
$7.83 M
|
$4.64 M
|
$1.29 M
|
$3.83 M
|
| Selling & Marketing Expenses |
-$4.31 B
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$4.10 M
|
$7.43 M
|
$7.83 M
|
$4.64 M
|
$1.29 M
|
$3.83 M
|
| Other Expenses |
$0.00
|
-$0.00
|
$2.70 M
|
-$9.53 M
|
-$3.00 M
|
$551,235.00
|
| Operating Expenses |
$10.43 M
|
$22.72 M
|
$30.95 M
|
$18.61 M
|
$10.80 M
|
$23.48 M
|
| Cost And Expenses |
$0.00
|
$22.92 M
|
$30.95 M
|
$18.61 M
|
$10.80 M
|
$23.48 M
|
| Interest Income |
$0.00
|
$463,256.00
|
$253,323.00
|
$2,431.61
|
$2,440.90
|
$1,560.87
|
| Interest Expense |
$0.00
|
$0.00
|
$253,323.00
|
$2.43 M
|
$2.44 M
|
$1.56 M
|
| Depreciation & Amortization |
$215,437.00
|
$204,617.00
|
$121,749.00
|
$77,960.00
|
$55,060.00
|
$36,816.00
|
| EBITDA |
-$10.57 M |
-$22.25 M |
-$30.83 M |
-$27.70 M |
-$13.74 M |
-$22.20 M |
| EBITDA Ratio |
0
|
0
|
-0.01
|
0
|
0
|
-32.2
|
| Operating Income Ratio |
0
|
0
|
-0.01
|
0
|
0
|
-32.31
|
| Total Other Income/Expenses Net |
-$134,563.00
|
$463,246.00
|
$2.96 M
|
-$1.85 M
|
-$1.60 M
|
-$1.52 M
|
| Income Before Tax |
-$10.78 M
|
-$22.46 M
|
-$27.99 M
|
-$30.21 M
|
-$16.24 M
|
-$23.80 M
|
| Income Before Tax Ratio |
0
|
0
|
-0.01
|
0
|
0
|
-34.51
|
| Income Tax Expense |
-$10.77 B
|
$0.00
|
-$3.21 M
|
-$7.10 M
|
-$560,381.00
|
$2.11 M
|
| Net Income |
-$10.78 M
|
-$22.46 M
|
-$24.78 M
|
-$23.11 M
|
-$15.68 M
|
-$25.91 M
|
| Net Income Ratio |
0
|
0
|
-0.01
|
0
|
0
|
-37.58
|
| EPS |
-285.82 |
-0.65 |
-0.74 |
-0.69 |
-0.47 |
-0.78 |
| EPS Diluted |
-285.82 |
-0.65 |
-0.74 |
-0.69 |
-0.47 |
-0.78 |
| Weighted Average Shares Out |
$3.77 M
|
$34.36 M
|
$33.67 M
|
$33.48 M
|
$33.09 M
|
$33.09 M
|
| Weighted Average Shares Out Diluted |
$3.77 M
|
$34.36 M
|
$33.67 M
|
$33.48 M
|
$33.09 M
|
$33.09 M
|
| Link |
|
|
|
|
|
|
